Overview

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

Status:
Not yet recruiting

Trial end date:
2030-02-28

Target enrollment:

Participant gender:

Summary

This study (phase I clinical trial and expansion cohorts) will evaluate safety and efficacy of combination of atezolizumab and tiragolumab, with concomitant or sequential SBRT for four oligometastatic cancer cohorts. This study will allow to developpe one or several randomized Phase II clinical trials for the more promising indications

Phase:

Phase 1

Details

Lead Sponsor:

Centre Georges Francois Leclerc

Treatments:

Atezolizumab